annb0t
Top 20
ResMed RMD continues to see growth in the patient diagnosis trends in sleep apnea, COPD and asthma. The company is expecting an increase in digital health demand with the adoption of digital healthcare management systems. The stiff competition faced by ResMed is worrying. This apart, reimbursement issues and competitive bidding continue to affect the stock. ResMed currently carries a Zacks Rank #3 (Hold).
In the past year, ResMed has outperformed its industry. The stock has lost 23.5% compared ...
>>> Read more: ResMed (RMD) Gains on Product Uptake Even as Expenses Rise
In the past year, ResMed has outperformed its industry. The stock has lost 23.5% compared ...
>>> Read more: ResMed (RMD) Gains on Product Uptake Even as Expenses Rise
